Long-Term Outcomes of Transoral Surgery with Risk-Adapted Adjuvant Therapy in HPV-Positive Oropharyngeal Cancer: Results from the E3311 Trial
The E3311 phase II trial shows excellent long-term survival with deintensified postoperative management after transoral surgery in HPV-associated oropharyngeal cancer, with most patients spared from high-dose radiation and chemotherapy.